Should You Invest in This Dividend King on the Dip?

JNJ is trading on the dip after a Q3 report that beat revenue expectations and lifted full-year guidance, but a weak medtech division is holding back the rally.

The pharmaceutical segment did the heavy lifting. Cancer drug Darzalex and autoimmune treatment Tremfya drove the strength, according to the report. Management's decision to raise full-year guidance signals confidence in that momentum.

Medtech was the soft spot. The division underperformed, with safety concerns around Impella heart pumps cited as a particular drag. That split defines the setup: a pharma-led beat against a device-side problem that has yet to clear.

The bull case rests on longer-term factors. The Motley Fool piece points to a robust pharmaceutical pipeline and upcoming medtech innovations, including robotic surgery devices. It also highlights JNJ's status as a Dividend King, with 64 consecutive years of dividend increases.

Interpretation: a revenue beat plus raised guidance usually supports the thesis, so the dip appears tied to medtech worries rather than a deterioration in the pharma engine. Whether that gap is a buying opportunity depends on how quickly the Impella issue resolves.